Silodosin Treatment for Benign Prostatic Hyperplasia (BPH)

Clinical Guidelines and Recommendations

• The American Urological Association (AUA) recommends silodosin as one of several alpha blockers for treating patients with bothersome, moderate to severe Lower Urinary Tract Symptoms (LUTS)/BPH, with the choice of alpha blocker based on patient age, comorbidities, and different adverse event profiles 1
• For patients with prostatic enlargement (>30cc), the AUA suggests considering combination therapy with a 5-alpha reductase inhibitor for long-term management and prevention of disease progression 1, 2